Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations tha...

Descripción completa

Detalles Bibliográficos
Autores: Gonzalez Cao, Maria, Puertolas, Teresa, Riveiro, Mar, Muñoz Couselo, Eva, Ortiz, Carolina, Paredes, Roger, Podzamczer Palter, Daniel, Manzano, Jose Luis, Molto, Jose, Revollo, Boris, Carrera Álvarez, Cristina, Mateu, Lourdes, Fancelli, Sara, Espinosa, Enrique, Clotet, Bonaventura, 1953-, Martínez Picado, Francisco Javier, Cerezuela, Pablo, Soria, Ainara, Marquez, Ivan, Mandala, Mario, Berrocal, Alfonso, Spanish Melanoma Group (GEM).
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/176933
Acceso en línea:https://hdl.handle.net/2445/176933
Access Level:acceso abierto
Palabra clave:Melanoma
Immunoteràpia
Càncer
Immunotheraphy
Cancer
Descripción
Sumario:Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.

Similares en LA Referencia